-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UM3KcgMcbfWN78oJXjW5dA1BPIz4xD3nrAGW/lnA2LidBSKdNMdPzO9DkCMk0l6F 4YHU2w3egFGeQQfaGJxl8w== 0001108890-08-000162.txt : 20080715 0001108890-08-000162.hdr.sgml : 20080715 20080715130045 ACCESSION NUMBER: 0001108890-08-000162 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080531 FILED AS OF DATE: 20080715 DATE AS OF CHANGE: 20080715 EFFECTIVENESS DATE: 20080715 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncologix Tech Inc. CENTRAL INDEX KEY: 0000799694 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 861006416 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-15482 FILM NUMBER: 08952397 BUSINESS ADDRESS: STREET 1: P.O. BOX 8832 CITY: KENTWOOD STATE: MI ZIP: 49518-8832 BUSINESS PHONE: 616-977-9933 MAIL ADDRESS: STREET 1: P.O. BOX 8832 CITY: KENTWOOD STATE: MI ZIP: 49518-8832 FORMER COMPANY: FORMER CONFORMED NAME: BESTNET COMMUNICATIONS CORP DATE OF NAME CHANGE: 20001219 FORMER COMPANY: FORMER CONFORMED NAME: WAVETECH INTERNATIONAL INC DATE OF NAME CHANGE: 19980225 FORMER COMPANY: FORMER CONFORMED NAME: WAVETECH INC DATE OF NAME CHANGE: 19920703 NT 10-Q 1 oncologixnt10qsb053108.txt PERIOD ENDED 05-31-08
----------------------------- UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION ----------------------------- Washington, D.C. 20549 OMB Number: 3235-0058 Expires: March 31, 2006 Estimated average burden FORM 12b-25 hours per response ..... 2.50 ----------------------------- ----------------------------- NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-15452 (Check One): ----------------------------- ----------------------------- | | Form 10-K and Form 10-KSB |_| Form 20-F |_| Form 11-K |X| Form 10-Q and Form 10-QSB CUSIP NUMBER |_| Form N-SAR 68230M100 For Period Ended: May 31, 2008 ----------------------------- ------------------- [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: _______________________________________________________________________ - ------------------------------------------------------------------------------------------------------------------------------------ Read Attached Instruction Sheet Before Preparing Form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. - ------------------------------------------------------------------------------------------------------------------------------------ If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: - ------------------------------------------------------------------------------------------------------------------------------------ PART I -- REGISTRANT INFORMATION - ------------------------------------------------------------------------------------------------------------------------------------ Full Name of Registrant Oncologix Tech Inc. - ------------------------------------------------------------------------------------------------------------------------------------ Former Name if Applicable BestNet Communications Corp. & Wavetech International, Inc. - ------------------------------------------------------------------------------------------------------------------------------------ Address of Principal Executive Office (Street and Number) P.O. Box 8832 - ------------------------------------------------------------------------------------------------------------------------------------ City, State and Zip Code Grand Rapids, MI 49518-8832 - ------------------------------------------------------------------------------------------------------------------------------------ PART II -- RULES 12b-25(b) AND (c) If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) [ ] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; [X] (b) The subject annual report, semi-annual report or transition report on Form 10-K, Form 10-KSB, Form 20-F, Form 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or Form 10-QSB, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and [ ] (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. PART III -- NARRATIVE State below in reasonable detail the reasons why Forms 10-K and 10-KSB, 20-F, 11-K, 10-Q and 10-QSB, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed period. As reoprted on our Current Form 8-K filed on March 20, 2008, we iiues a press release pertaining to discussions, with another company in the industry, of a possible arrangement for the transfer of its Oncosphere assets. We are currently working on finalizing funding an Asset Purchase Agreement with this other conpany. We still continue to seek additional funding but cannot be that assured any additional funding will be possible. Additional time is required to analyze the effect of these results on our financial statements and future going concern. (Attach Extra Sheets if Needed)
SEC 1344 (3/06) PART IV--OTHER INFORMATION (1) Name and telephone number of person to contact in regard to this notification Michael A. Kramarz (616) 977-9933 - --------------------------------------- --------------------- ---------------- (Name) (Area Code) (Telephone Number) (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). [X] Yes [_] No -------------------------------------------------------------------------------------------------------------------------------- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [ ] Yes [X] No If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. ==================================================================================================================================== Oncologix Tech Inc. ------------------------------------------ (Name of Registrant as Specified in Charter) has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 15, 2008 By: /s/ Michael A. Kramarz --------------------------- ---------------------------------------- Michael A. Kramarz, Chief Financial Officer INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form. - ----------------------------------------------------------- ATTENTION -------------------------------------------------------------- Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). - ------------------------------------------------------------------------------------------------------------------------------------
-----END PRIVACY-ENHANCED MESSAGE-----